That's because the convergence of DNA editing, artificial intelligence, and gene therapies, importantly CRISPR gene editing, is going to cure disease." Editas is generating much higher gains today than the other leading CRISPR-focused biotech, CRISPR Therapeutics (CRSP -5.54%), though. That's probably due to a couple of factors.
Full Answer
Is Editas Medicine's stock a good value?
Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may …
Why is Editas outperforming other gene-editing stocks this year?
Apr 25, 2022 · As of April 22, 2022, Editas Medicine Inc had a $1.1 billion market capitalization, compared to the Biotechnology & Medical Research median of $133.1 million, Editas Medicine Inc’s stock is down 44.1% in 2022, down 5.5% in the previous five trading days and down 60.5% in the past year. Currently, Editas Medicine Inc’s price-earnings ratio is .
What does Editas Medicine DO?
Apr 25, 2022 · Based on estimates by 17 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 7 have rated the Editas Medicine Inc. (EDIT) stock as a Hold, while 6 rate it as a Buy. 1 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 3 suggest the stock as a Sell.
Why has Editas stock grown 3 consecutive days?
Apr 14, 2022 · Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents finance.yahoo.com - March 1 at 5:31 PM: Editas Medicine (NASDAQ:EDIT) adds US$129m to market cap in the past 7 days, though investors from a year ago are still down 61% finance.yahoo.com - February 28 at 9:12 AM
Is Editas stock a good buy?
The Editas Medicine, Inc stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Will Moderna buy Editas medicine to jump into gene editing?
Also, Moderna likely won't limit itself to acquisitions. The company could choose to partner with one or more gene-editing biotechs instead of buying any of them outright. However, look for Moderna to move forward with its plans to expand into gene editing sooner rather than later.Aug 12, 2021
Why did edit stock go up?
That's because the convergence of DNA editing, artificial intelligence, and gene therapies, importantly CRISPR gene editing, is going to cure disease." Editas is generating much higher gains today than the other leading CRISPR-focused biotech, CRISPR Therapeutics ( CRSP -2.01% ), though.Dec 21, 2020
Who invested in Editas?
Top 10 Owners of Editas Medicine IncStockholderStakeTotal changeThe Vanguard Group, Inc.10.70%+12.99%BlackRock Fund Advisors6.85%+0.94%ARK Investment Management LLC6.16%-33.01%SSgA Funds Management, Inc.4.78%+51.74%6 more rows
Is there a Crispr ETF?
Here are the top five ETFs that focus on CRISPR gene editing....Best CRISPR and gene-editing ETFs.ETFExpense RatioARK Genomic Revolution ETF (NYSEMKT:ARKG)0.75%Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)0.5%3 more rows•Dec 18, 2021
Does Editas own Crispr?
The Editas license covers patents for CRISPR/Cas9 and CRISPR/Cas12a gene editing in all human cells, the company said. Editas' shares climbed over 10% in after-market trading Monday to $18.90 apiece.
Why is edit stock down?
The stock price of Editas plunged 19% in yesterday's trading session after the company shared interim data for its EDIT 101 - a CRISPR-based treatment for Leber congenital amaurosis.Oct 1, 2021
Why is Editas stock going down?
One reason behind the analyst's bearish sentiment is Editas Medicine's EDIT-101, a potential treatment for a rare eye disease called Leber congenital amaurosis. Initial results do not indicate that EDIT-101 could meaningfully improve patients' vision, according to Kumar.Apr 16, 2021
What is edit medicine?
Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world.
Does Ark own Editas?
In addition to Editas, CRISPR Therapeutics, and Beam, the ARK Genomic Revolution ETF owns shares in Intellia Therapeutics, Caribou Biosciences, and Cellectis. The ARK Innovation ETF also owns a position in Intellia.Sep 23, 2021
Who owns Editas medicine?
Editas MedicineTypePublicFoundersJennifer Doudna, Feng Zhang, George Church (geneticist), David R. Liu, J. Keith JoungHeadquartersCambridge, Massachusetts , United StatesNumber of locations2Key peopleJames Mullen (President and CEO)8 more rows
How does Editas medicine work?
Our work on autologous cell medicines is focused on editing T cells, a type of immune cell, to improve their ability to detect and attack cancer cells in the body. Certain tumors are able to interfere with the activity of T cells by creating suppressive microenvironments.
About Editas Medicine
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R.
Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 3 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Editas Medicine stock.
Here are some best guesses about the biotech stock's huge jump
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of Editas Medicine ( NASDAQ:EDIT) were skyrocketing 41.5% higher as of 11:57 a.m. EST on Monday. The company didn't announce any big news over the weekend or today, so why is the stock taking off?
So what
Huge jumps like Editas is delivering today are exciting. However, investors probably shouldn't become overly exuberant. Sometimes stocks can go down even more quickly than they go up.
Now what
The important things to watch with Editas going forward are the results from its clinical studies. Editas has encountered some enrollment challenges with its phase 1/2 study of EDIT-101 due to the COVID-19 pandemic. The rollouts of new coronavirus vaccines could help alleviate those issues in the first half of 2021.
What happened
Shares of Editas Medicine ( EDIT 6.56% ) were up 13.9% as of 10:47 a.m. EST on Wednesday. This marked the third consecutive day of double-digit gains for the stock after Editas announced new data over the weekend for its experimental gene-editing therapy EDIT-301 at the American Society of Hematology (ASH) annual meeting.
So what
There are probably two factors at play with Editas' big jump over the last three days. Obviously, investors remain bullish about the prospects for EDIT-301. Editas reported high levels of gene editing in red blood cells of patients with sickle cell disease.
NASDAQ: EDIT
CRISPR Therapeutics' program is farther along than EDIT-301 is and has had positive results so far from an early stage clinical study. That's the main reason its shares have risen more than Editas. However, my hunch is that the latter's latest announcement has caused many investors to recognize the potential that Editas has.
Now what
The next potential catalyst for Editas could be right around the corner. The company expects to file for approval with the Federal Drug Administration (FDA) by the end of 2020 to begin a phase 1/2 study of EDIT-301 in treating sickle cell disease.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
